K
Karla V. Ballman
Researcher at Cornell University
Publications - 390
Citations - 34158
Karla V. Ballman is an academic researcher from Cornell University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 78, co-authored 353 publications receiving 29127 citations. Previous affiliations of Karla V. Ballman include University of South Florida & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Laura Madanat-Harjuoja,Kelly Klega,Yaoyong Lu,David S. Shulman,Aaron R. Thorner,Anwesha Nag,William D. Tap,Denise K. Reinke,Lisa Diller,Karla V. Ballman,Suzanne George,Brian D. Crompton +11 more
TL;DR: The results demonstrate that detection of ctDNA is associated with outcome and objective response to chemotherapy in patients with advanced LMS and suggest that liquid biopsy assays could be used to inform treatment decisions by recognizing patients who are likely and unlikely to benefit from chemotherapy.
Journal ArticleDOI
CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin.
Gregory M. Cote,Sant P. Chawla,Melissa Amber Burgess,Katherine Anne Thornton,Robert K. Oldham,Scott H. Okuno,Karla V. Ballman,Susan Matlow,Daryl Barnett,Steven Attia +9 more
TL;DR: This data indicates that P-glycoprotein 1 (P-gp), a cell membrane drug, may be a viable alternative to anthracycline for the treatment of soft tissue sarcomas.
Journal ArticleDOI
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
Shilpa Gupta,Karla V. Ballman,Matthew D. Galsky,Michael J. Morris,Srikala S. Sridhar,Ronald C. Chen,Timothy A. Chan,Yujia Wen,Petros Grivas,Alan Tan,Shiva Baghaie,Jonathan E. Rosenberg +11 more
TL;DR: The MAIN-CAV trial as discussed by the authors is a randomized, multicenter, international trial for locally advanced/mUC patients who do not progress after 4-6 cycles of any platinum-based chemotherapy (gem-cis, gem-carbo, MVAC or ddMVAC).
Journal ArticleDOI
Axillary vs Sentinel Lymph Node Dissection for Invasive Breast Cancer—Reply
Journal ArticleDOI
Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target.
Jennifer A. Crozier,Brian M. Necela,E. Aubrey Thompson,Xochiquetzal J. Geiger,Alvaro Moreno-Aspitia,Ann E. McCullough,Barbara A. Pockaj,Heather E. Cunliffe,Zhifu Sun,Krishna R. Kalari,Jennifer M. Kachergus,Daniel J. O'Shannessy,Julia D. Maltzman,Karla V. Ballman,Cathy A. Andorfer,Edith A. Perez +15 more
TL;DR: A large number of breast cancer tumors including 4 benign, 33 ER+, 26 HER2+, and 68 triple negative (TN) were constructed into tissue microarrays (TMAs) and FRA expression was analyzed by immunohistochemistry using a high affinity FRA antibody.